

REMARKS

The Office submitted that in accordance with 37 C.F.R. § 1.175(b)(1), a supplemental reissue oath/declaration must be received before this reissue application can be allowed. Claims 1, 25, and 26 were rejected as being based upon a defective reissue oath/declaration under 35 U.S.C. § 251, and the nature of the defect was set forth above. The Office further submitted that receipt of an appropriate supplemental oath/declaration under 37 C.F.R. § 1.175(b)(1) will overcome the rejection under 35 U.S.C. § 251.

Applicants include herewith the supplemental declaration pursuant to 37 C.F.R. § 1.175(b)(1) as requested by the Office.

In view of the attached supplemental declaration, reconsideration and withdrawal of the rejection is respectfully requested. Applicants respectfully submit that claims 1, 25, and 26 are in condition for allowance and allowance of claims 1, 25, and 26 in the present Reissue Patent Application is kindly solicited.

Respectfully submitted,

/Nelsen L. Lentz/

Nelsen L. Lentz
Attorney for Applicants
Registration No. 38,537
Telephone No. (317) 276-1207

Patent Division
Eli Lilly and Company
P. O. Box 6288
Indianapolis, Indiana 46206-6288

August 30, 2006